Britain and America have reached a major trade agreement that will guarantee zero import taxes on UK medicine products entering the American market.
The Terms of the Pact
As part of the deal, the UK has committed to raise expenditure on medicines through the National Health Service (NHS). This move guarantees that duties on these key products will stay at nothing for a period of the next three years.
This agreement follows previous threats to significantly raise duties on patented drug products, with figures floated reaching double the cost.
"This arrangement between the UK strengthens the worldwide climate for new treatments and introduces long-overdue fairness to American-British drug exports," an announcement noted.
Economic Impact
Pharmaceuticals are one of the UK's biggest export categories to the US, which is easily the biggest market for leading companies like GSK and AstraZeneca.
Export figures show that in the 12 months leading up to the third quarter, the UK exported medicines worth over eleven billion pounds to the US. This amount made up 17.4% of total UK exports in that period.
"This agreement secures jobs, increases funding and facilitates the UK to establish itself as a global hub for medical research," a government official commented.
Detailed NHS Changes
The pact entails several notable pledges from the United Kingdom:
- Price Threshold Increase: The UK will raise the cost ceiling at which it judges new treatments to be too expensive by twenty-five percent.
- Increased NHS Spending: There is a aim to raise total NHS spending on medicines from 0.3% of GDP to 0.6% over the next decade.
- Rebate Cap: The sum pharmaceutical firms must return to the NHS to stay within budget will be restricted at 15%. In the past, refunds were more than twenty percent.
Broader Context
The pact takes place against a protracted row between the drug companies and the ministers over spending levels and regulatory access.
These tensions were exacerbated by arguments that American patients were paying several times more for the identical medicines than consumers in the other developed nations.
Recently, several major drug company projects in the UK have been delayed or cancelled, while multi-billion-dollar funding commitments have been announced toward US facilities.
The Science Minister publicly accepted that the NHS needed to spend more on treatments, noting that its budget allocation on drugs had declined as a proportion of its overall budget over the last ten years.
